šŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Rigel Pharmaceuticals, Inc. (RIGL)
NASDAQ: RIGL Ā· Real-Time Price Ā· USD
41.19
-1.34 (-3.15%)
At close: Nov 19, 2026, 4:00 PM EST
40.50
-0.69 (-1.68%)
After-hours: Nov 19, 2026, 7:30 PM EST
← View all transcripts

Jefferies Global Healthcare Conference

Nov 17, 2026

Summary

VEPPANU’s launch generated $6.6 million in its first six weeks and targets a U.S. segment with potential above $1 billion. R289 dose-expansion data were expected at ASH in December 2026, with a registrational study planned for 2027 subject to FDA concurrence.

Farzin Haque
Biotechnology Analyst, Jefferies

Hi, everyone. Let's get started. My name is Farzin Haque, one of the biotech analysts at Jefferies. It's my pleasure to introduce Raul Rodriguez, CEO of Rigel Pharmaceuticals. He's going to present us, and we can take some questions at the end if we have any. Thank you for joining us, Raul.

Raul Rodriguez
CEO, Rigel Pharmaceuticals

Thank you, Farzin, and thank you to our colleagues at Jefferies for the invitation. It's a pleasure to be with you today. Importantly, these are our forward-looking statements, important statements about my presentation for you today. It's a lot of small print, but it is available on our website for you to review at your leisure. Let me tell you about Rigel. Rigel is a company that has gone through several transformations of the company, and really, it's exciting to be at a company where every few years, it's very much a different company. I'll tell you what we've done in the recent past, and in this presentation, what our plans are going forward. Our transformational growth strategy has four key strategic objectives. Grow our commercial business.

In this presentation, I'll show you how we've grown it to date, what our plans are for the future. In-license or bring in additional molecules to add to our portfolio and our pipeline, and I'll show you what we've done over the last several years, what our plans are for the future of that. Advance our pipeline. Here, we'll discuss one of the really exciting opportunities that we have in terms of our own pipeline that's coming forward, and we'll have data next month at the ASH meeting.

All this is coupled together with financial discipline, maintaining financial discipline so we can afford to do and pay for what we're proposing to do here today. I'll share with you some of the latest results in that. All four of these strategic objectives work together. They're interlocking and codependent, and it's important to execute across all of them. I hope at this presentation, I can demonstrate to you how exactly we're doing that.

Let me start here with one of our most recent examples of this strategy in action. VEPPANU is a product we acquired in Q3. The deal closed in June. We began working on introducing the product immediately after that, and ahead of commercial availability. We incorporated it into our distribution network and immediately began working all the contractual things to get those done so that we could have this product available to patients very quickly. In the first six weeks, it launched mid-August, we were able to achieve $6.6 million in sales. Really impressive number. That was over 100 patients in clinics received product in that six-week period. Many of them, of the early patients, received, the majority, in fact, received their first refill even within Q3, which is a very good early sign.

We have strong coverage across commercial and Medicare payers, and healthcare provider engagement has been going very well as we focus on high prescribers in metastatic breast cancer in this area. We are executing on our plan, highlighting the data that we have supporting VEPPANU and its approval, and its differentiated mechanism of action. I will tell you a bit more about that in a minute. An exciting Q3, one of the most exciting times in our history in having a new growth engine for the company. How are we doing in terms of growing the commercial business? Quite good.

Here we see what we have done over the last five years, where we have grown our commercial business by an average of 35% per year over this period of time. TAVALISSE, our main product in deep green there, has grown very nicely in this period.

Subsequently, we have added REZLIDHIA in 2022, and you begin to see that in light green. Then we added GAVRETO in 2024, in deeper green. Our guidance is to continue to grow that, excluding even VEPPANU. What is exciting about this is what is coming in the future. VEPPANU will be our potential largest product at the company, and it is a significant opportunity in a very large market. It will be the driver of growth for our business in the near term and in the intermediate term. We are very excited about the VEPPANU opportunity for us. In the more intermediate and longer term, the key driver of growth will be R289, our internally discovered molecule. It is an IRAK1/4 inhibitor, which we have in development for lower-risk MDS.

This has a potential to be greater than a billion-dollar opportunity and will drive the commercial growth of the business in 2030s and beyond. I will tell you a little bit more about each of these two molecules that are the near-term and the longer-term future for the growth of the business. This past quarter, we achieved $72 million in net product sales, our largest quarterly sales number ever. VEPPANU contributed $6.6 million, TAVALISSE continued to grow and generated $4.6 million, REZLIDHIA $9.9 million, and GAVRETO $9.8 million.

A little bit of decline there in sales. It is a very stable product, generally selling about $10 million a quarter. Overall, for the three quarters of this calendar year, very nice growth over last year comparable period, as you see here. A very good quarter for us in Q3, in addition to launching VEPPANU.

VEPPANU is indicated for patients that are ER-positive, estrogen receptor-positive, HER2-negative, and have an ESR1-mutated advanced or metastatic breast cancer patients. To tell you a little bit about the market opportunity, in the U.S., there are about 170,000 metastatic breast cancer patients. Of those, about 119,000 are ER-positive, HER2-negative patients. Of those patients, after endocrine and CDK4/6 therapy, generally ESR1 mutations evolve, and that accounts for about 47,000 patients. Of those, about 28,000 are diagnosed having this mutation, and about 20,000 are treated in the second line and beyond, which is where we are indicated. That 20,000 patients are an attractive market opportunity. If you think about the numbers associated with it is well over a billion dollars opportunity in that segment of the population.

We're excited about the product, and with it, what we were able to deliver in the first six weeks only, 100 patients. As I mentioned, most of those received their second refill, their second shipment. We reached many prescribers and many accounts over the six-week period, and we continue to make very good progress on these. This is available on our website, by the way. Exciting also is that we were able to receive lots of high prior authorization rates, 88% overall, 90%+ for Medicare, 80%+ for commercial insurance at this point. So very attractive.

We were able to get the product to patients very quickly, median of four days for these patients in this first six weeks of product. So quick to get the patients to get their drug, and we provide a wide range of support to these patients.

This is a hub that we had in place prior, so now we've added this as a product. So we were able to leverage that very nicely in helping them get coverage support and other assistance that is compliant so that we can help them access the product. Let me tell you what excited us the most about VEPPANU. It's a PROTAC, which is different than any other drug that's out there today, cancer or not cancer. It's an area of tremendous focus in terms of how we address molecules in difficult-to-target areas such as this.

It's established that estrogen receptor degradation is an important therapeutic approach to treating this type of metastatic breast cancer. The other SERDs, the more traditional approach, is to have a molecule that binds to the estrogen receptor and changes its conformation, causes it to be more likely to be degraded.

There's degradation, and the degradation, as we've seen in the preclinical studies, have been wide-ranging. With PROTAC, it's a very different approach. PROTAC uses the cell's own disposal system to get rid of unwanted protein. What the molecule does, it's a bifunctional molecule. One side attaches to the estrogen receptor, the other to ubiquitin E3 ligase. It brings those two close together in terms of where they sit, and then the ER is polyubiquitinated with tiny little ubiquitin proteins. Once that happens, that tags it for destruction by the cell's proteasome, and things are destroyed, the PROTAC molecule is released, and does this again and again and again. The consequence of that is that we have a high level of ER degradation with the PROTAC, as you see here.

So we're excited about having this novel mechanism in this area, and we focused on that elegant process and the results that it produced. It produced five months of progression-free survival, PFS, versus fulvestrant, an older SERD, only producing 2.1 months. This is part of our registrational study and is part of the label. So we're excited about having something that is the first and only approved PROTAC that has features that make it a very attractive molecule in this breast cancer space. Let me move on to in-licensing and business development. Here, we've been very successful over the last handful of years. We're looking for assets that are differentiated in hematology, oncology, and related areas. In 2022, we acquired REZLIDHIA and launched it in 2022. This is indicated for relapse refractory IDH1 mutant AML. In 2024, we acquired GAVRETO.

This is a product that is indicated for RET-positive non-small cell lung cancer and thyroid cancer, and we launched that product in 2024. In 2026, yet again, we acquired VEPPANU, and we've launched the product in August of 2026. So every two years, we seemingly are able to acquire a new product, launch it, integrate it into our system, and work to making it a success. We're looking for late-stage programs, things that have completed their registrational trial, and either are at NDA review or NDA is coming shortly, or the product's just been approved. So we're able to launch it very quickly after we acquire the product. It's important that they are synergistic to our current commercial effort, so we don't have to grow our commercial business too much infrastructure in order to launch that product.

What that creates, because it's a late-stage product, we integrate it, we launch it quickly, is that it rapidly becomes accretive and cash-generating. That's a very attractive feature of all these three products that we acquired in the last handful of years. So, excited about that opportunity. We'll continue to further this strategy and look at additional molecules that we could bring in that are synergistic to what we have. Let me move to our development pipeline. I'd like to tell you a little bit about the first two things on this slide. R289 is our IRAK1/4 inhibitor in development in a phase I-B study for relapse refractory lower-risk MDS. And we're going to soon consider other indications and lines of therapy for this molecule. I'll tell you quite a bit more about this.

Vepdeg, which is VEPPANU, is a PROTAC, and we have ongoing studies in combinations with our partner, Arvinas and Pfizer. They're completing a bunch of studies. I'll share those with you. And we're considering which studies ourselves to launch going forward to highlight the mechanistic differences of this molecule and how it's useful in a post-SERD setting. I won't talk very much about olutasidenib or REZLIDHIA further, but we are working with strategic collaborations. MD Anderson is one of our largest collaborators in exploring how olutasidenib in monotherapy and combination therapy work in IDH1-mutant AML and other malignancies. And with another organization, the CONNECT Group, we're working on studying this molecule in high-grade gliomas as well. But I'll talk about the first two a bit more. R289 in lower-risk MDS. Here's the landscape for lower-risk MDS.

MDS is a clonal disorder where there's something going on in the bone marrow that precludes normal hematopoiesis. For example, there's substantial and inflammatory process in the bone marrow, and that inflammatory, let's call it a cytokine storm in the bone marrow, is what crowds out normal hematopoiesis. So these patients, as a consequence, are highly anemic. They don't have enough red blood cells. The primary goal of therapy in MDS is to take patients that are transfusion dependent, some of these patients get transfusions every couple of weeks in order to survive, is to get that type of patient that's transfusion dependent and get them to transfusion independence. That's the primary objective.

There are drugs approved in this category, but unfortunately, they have modest efficacy. I'll share that with you in a second. First line of therapy is typically an erythroid-stimulating agent, ESAs.

Luspatercept is now beginning to make some progress in that first line. If you are a del(5q) patient, you can use lenalidomide. Failing that first line, you go into generally luspatercept, if you have not done that in the first line, or imetelstat, which is approved more recently. Luspatercept here gives you about a 38% response rate. That is, 62% of patients do not succeed on luspatercept. Imetelstat is about 40%. Similarly, about 60% of patients do not succeed on imetelstat. Failing that, you may go to HMAs. There are a couple of them.

The response rates there are 18%-20%. That is, about 80% of patients do not succeed on those either. So a poorly treated range of different approaches here. We think that R289 has potential to play well in the highly refractory patient population. I will show you some of the data that is from our current study.

After luspatercept, sliding in ahead of HMAs. Keep in mind, HMAs only give an 18% or 20% response rate, so you would have to beat that, not a high bar. Or maybe even ahead of luspatercept in that post-ESA, maybe post-first-line ESA, luspatercept area. That is a sizable patient population. Luspatercept is a $2 billion run rate product right now. So there are exciting opportunities in each of these three segments. Here is the value proposition for R289. There are about 12,000+ patients with lower-risk MDS that were previously treated, and as I mentioned to you, the mechanism of this MDS is a hyperinflammatory response in the bone marrow. That dysregulation is driven by a number of pro-inflammatory families, Toll-like receptor and IL-1 signaling. IRAK1/4 very effectively reduces IL-1 signaling and Toll-like receptor signaling.

It is able to control this pro-inflammatory cascade, allowing for normal hematopoiesis to resume in the bone marrow, addressing the anemia that is underlying the low-risk MDS. We have clinical proof of concept in healthy volunteers that this is the effect of this product, reducing cytokine release. We have Fast Track designation and orphan drug designation for the product from the FDA. I will share some of the data that is coming that we presented at the ASH meeting. It is very promising early data, last year's ASH. This is a study we are concluding. It has a dose escalation phase where you study the product at different doses, each of these dose groups about six patients. With that, you selected two doses. We selected 500 once a day and 500 BID, and are now completing the dose expansion phase.

20+ patients is what we will have in each of those two doses. We will compare the two, select the one that we think works the best from efficacy and safety profile, and then move forward with that dose. We will also start an early patient study in the post-ESA area, as you see in the little blue box as well, with that dose, to explore how well the patient does that are much earlier on in their course of disease treatments. We will have updated data on the dose expansion phase at the ASH meeting in December in a few weeks.

That will be a very exciting release for us. We did submit an abstract based on a July data cut. That was part of the abstract. I want to highlight a few things for you there. The median number of prior therapies, three. These are highly refractory patients.

84% of them have been through luspatercept, 83% through ESAs, 60-some percent through one of the two azacitidine and decitabine HMAs. A third, 29% had used some investigational agents. It tells us there's a real need for patients in this highly refractory segment of the market. Despite the patients being highly refractory and treatment experienced, the AE profile was actually quite good. Diarrhea was 31%, cough, all grade one and two. We didn't have discontinuation in this data cut for treatment-emergent AEs, and no dose-limiting toxicities during the dose expansion phase.

We will now produce a new data cut in November, which will be the basis of our presentation at the ASH meeting in a couple weeks, a few weeks. That presentation will be given by Dr. Garcia-Manero, the principal investigator of the study and Chairman of the Leukemia Department at MD Anderson.

It's on Saturday, December 12th, at 3:00. It should be a very exciting presentation for us because we can highlight now with a robust dataset how well the patients are doing at these two dose groups and which one we think we want to go forward with. Please be on the lookout for that. Our next steps in the R289 development plan is to complete enrollment, select the recommended dose, we'll do that shortly, share that data at the end of this year at the ASH meeting, start that small study, and very importantly, engage with FDA on what the registrational study will be. Our plan is to start the registrational study in 2027 with the FDA concurrence on this. It's going to be an exciting year next year as we launch our large registrational study in this area.

We're also going to evaluate other indications and other lines of therapy within MDS. As I said to you, there's several other opportunities where we can go forward with that we're excited about. The oral presentation is going to be presented, and then we have other things that we're presenting at this ASH meeting in the form of poster presentations. Let me talk a little bit about our clinical plans for vepdegestrant or VEPPANU. Our partners, Pfizer, is completing a number of studies that we hope to bring to fruition. These include four combinatorial studies. We're combining with different agents, and they'll provide us that data. These are fully enrolled now. They're concluding the studies. We'll have the data to share, I hope sometime next year, so we can discuss how well the product works with these other agents.

In addition, for our own internal development, we want to focus on combination studies, and especially in the post-SERD setting. As SERDs are approved and they're used earlier on, that gives us an opportunity to take a slot after them, and that becomes a very attractive market segment. We're the only non-SERD available, and so therefore, as a PROTAC, we should be able to make great progress with data in the post-SERD setting. Already at the ASH meeting, we are presenting some initial data in the post-SERD setting. Limited number of patients as yet, maybe 19 patients, showing good efficacy with our product in patients that had previous SERD experience.

We are planning on launching additional studies ourselves and with academic partners to study different segments of post-SERD, as well as looking at real-world data to generate data in this segment to establish the product well in the post-SERD setting, including with various combinations of other agents that are approved in this segment. We also have other areas that we are looking to present. I am sorry, this is at San Antonio Breast Cancer. Should have said that.

Other areas where we are pretty excited about the profile of the product, and we plan on having a robust presentation dataset for you at these various centers, led by really key people in this segment that were really excited to have this. All this has happened really at breathtaking speed. We only acquired the product in June, and already we are deeply into it and planning what the next steps for the product will be.

Let me conclude by discussing our financial discipline as our fourth strategic objective for the company. We worked hard on growing the top line for the product, and as you see here, quarterly results, Q3 of this year was our largest ever, assisted by VEPPANU, $6.6 million. Very substantial growth from earlier on and on a quarterly basis, so we are excited about that. We have good contribution from contract revenues from our licensees outside the U.S. TAVALISSE, we have licensed on a global basis to various parties.

You see some of them here. We are beginning to also license out REZLIDHIA and soon others as well. So, contract revenues from collaborators are quite sizable and adding nicely to us. Importantly, as you see Q3 here, this is our results just presented just recently. Q3 was our profitable quarter as well.

Profitable, despite the fact that we acquired VEPPANU in Q3 and paid that, despite the fact that we contributed to the development that Pfizer is concluding in this area, despite the fact that we are working on the launch of VEPPANU, and despite the fact that we are also expanding our efforts on R289.

All of that considered, it is still a profitable quarter for us. So, we are excited about that demonstration of really strong financial position for the company. We updated our guidance, tightened it on the top side. Revenues now of $290 million-$295 million comprise the product revenues of $255 million-$260 million, and contract revenues of approximately $35 million. None of this guidance includes VEPPANU sales. This is just our original three products. We also reaffirmed that for the year, we expect to be fully profitable this year, despite all the things that we are doing.

A very strong position for the company. 2026 has been a really excellent year for us, bringing in VEPPANU, a first PROTAC approved by FDA in the segment of metastatic breast cancer, integrating it, launching it successfully, having a lot of awareness and building adoption for the product, and growing the top line. Advancing our development pipeline with R289, concluding those studies, selecting the dose, and then discussing what the registrational plan is for next year. We will complete all of that and select other lines of therapy and potential indications that we might go forward with.

Financial discipline continues. We are going to be profitable this quarter, higher sales levels, and bringing in a new molecule notwithstanding. So, really exciting time to be at the company. I think we may have time for a single question, but not much else, I think. Thank you so much.

Farzin Haque
Biotechnology Analyst, Jefferies

One question with the company launch. You're already seeing like 70%-80% in the community setting. How does that inform your ramp? How should we think about it? Are you already ahead of the curve?

Raul Rodriguez
CEO, Rigel Pharmaceuticals

Yes, exciting. What Farzin noted is that we're seeing kind of equal penetra- half our scripts being in academic and half being in community settings. Usually, when you launch a new product, it's mostly academics. Eventually, it bleeds into the community. But we're seeing good community adoption early. What does that mean? I think what it means is that there's excitement about the novel mechanism. I would note that 80% of the patients are in the community setting, so it's not surprising that there's a lot of interest in that setting because there's so many patients.

So we're delighted to have good introduction to the academic centers, but also really happy that already on the community side, there is no hesitance to try the product. And I think that bodes well for us in the longer term. Thank you, Farzin. Thank you, everyone.